Effect of ONO-8539 on Transient Lower Esophageal Sphincterreluxation in healthy male volunteer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2017
At a glance
- Drugs ONO 8539 (Primary)
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- 05 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 09 May 2017 Primary endpoint (The number of Transient lower esophageal sphincter relaxations) has been met as per the results published at the Digestive Disease Week 2017.
- 09 May 2017 Results (n=10), presented at the Digestive Disease Week 2017